AZD-3514

From WikiMD's Medical Encyclopedia

Revision as of 19:18, 31 December 2024 by Prab (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

An investigational drug for prostate cancer


AZD-3514 is an investigational drug that has been studied for its potential use in the treatment of prostate cancer. It is a selective androgen receptor modulator (SARM) that works by inhibiting the androgen receptor signaling pathway, which is crucial for the growth and survival of prostate cancer cells.

Mechanism of Action[edit]

AZD-3514 functions by binding to the androgen receptor (AR) and inhibiting its activity. The androgen receptor is a type of nuclear receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone (DHT). In prostate cancer, the AR signaling pathway is often upregulated, leading to increased tumor growth and progression. By inhibiting AR signaling, AZD-3514 aims to reduce the proliferation of cancer cells and induce apoptosis.

Clinical Development[edit]

AZD-3514 has undergone several phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics in patients with advanced prostate cancer. Early-phase trials have shown that AZD-3514 can effectively reduce prostate-specific antigen (PSA) levels, a marker used to monitor prostate cancer progression. However, further studies are needed to fully establish its clinical benefits and potential side effects.

Pharmacokinetics[edit]

The pharmacokinetic profile of AZD-3514 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. AZD-3514 is administered orally and is absorbed into the bloodstream, where it is distributed to various tissues, including the prostate. It is metabolized primarily in the liver and excreted through the kidneys.

Potential Side Effects[edit]

As with many investigational drugs, AZD-3514 may have side effects. Commonly reported adverse effects include fatigue, nausea, and changes in liver function tests. It is important for patients to be monitored regularly during treatment to manage any potential side effects.

Research and Future Directions[edit]

Research on AZD-3514 is ongoing, with studies focusing on optimizing its therapeutic efficacy and minimizing side effects. Combination therapies with other anti-cancer agents are also being explored to enhance treatment outcomes for patients with prostate cancer.

Also see[edit]

Template:Prostate cancer drugs



Investigational drugs
General
Drug types
By condition
Regulatory agencies
Related topics
This investigational drug related article is a stub.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=AZD-3514&oldid=6088301"